Natural History Study in Pediatric Patients With STXBP1 Encephalopathy With Epilepsy

STXBP1 Encephalopathy With Epilepsy Clinical Trial

Official title:

A Phase 0 Non-interventional, Multi-center, Natural History Study in Pediatric Patients With Syntaxin Binding Protein 1 (STXBP1) Encephalopathy With Epilepsy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05462054
• Other study ID #: CAP-002-501
• Status: Not yet recruiting
• Start date: July 2023
• Est. completion date: January 2026

Study information

• Verified date: October 2022
• Source: Capsida Biotherapeutics, Inc.
• Contact: Medical Monitor
• Email: clinicaltrials[@]capsida.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective, non-interventional, longitudinal study designed to characterize the natural history of STXBP1 related encephalopathy with epilepsy, in participants ≤ <5 years of age.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: January 2026
• Est. primary completion date: January 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Day to 5 Years

Eligibility

Inclusion Criteria:

• Male or female, > 1 day to = 5 years of age at the time of informed consent.
• Diagnosed with seizure disorder
• Presence of a STXBP1 gene mutation. Historical documentation is sufficient to support eligibility for the study. Confirmatory testing will be obtained at baseline and performed by a CLIA certified laboratory
• Written informed consent provided by a parent or legal guardian

Exclusion Criteria:

• History of prior gene therapy treatment
• Current enrollment in an interventional study or has received an investigational drug within 30 days or fewer than 5 half-lives prior to screening visit, whichever is longer
• Treatment with any antisense oligonucleotide therapy within 6 months prior to screening and anticipate remaining on treatment throughout the study
• The presence of a confirmed mutation in a gene other than STXPB1 that is known to contribute to a neurodevelopmental disability
• Presence of a significant non-STXBP1 related central nervous impairment/behavioral disturbance that would confound the scientific rigor or interpretation of results of the study
• History of prematurity (defined as gestational age <35 weeks), interventricular hemorrhage, structural brain deficit or congenital heart disease
• Requires mechanical ventilation or non-invasive respiratory support such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) at the time of informed consent

Related Conditions & MeSH terms

• Brain Diseases
• Epilepsy
• Spasms, Infantile
• STXBP1 Encephalopathy With Epilepsy

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Capsida Biotherapeutics, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in neurodevelopmental parameters of adaptive behavior function over time utilizing the Vineland Adaptive Behavior Scales-II (VABS-II) Age-equivalent Scores	The Vineland Adaptive Behavior Scales, Second Edition (Survey Interview Form) is a measure of adaptive behavior in children, adolescents and adults. It yields an overall standard score (Adaptive Behavior Composite, ABC) and age standard scores in four domains. ABC scores have a mean of 100 and a standard deviation of 15 (range = 20 to 160). Higher scores suggest a higher level of adaptive functioning.	2 Years
Primary	Changes in neurodevelopment parameters over time utilizing an age appropriate assessment.	The determination of whether a patient received Bayley Scales of Infant Development-III (BSID-III) is based on an algorithm that includes the patient's calendar age and VABS-II age-equivalent score (See Outcome 1). The BSID-III is a series of measurements to assess the motor (fine and gross), language (receptive and expressive), and cognitive development of infants and toddlers and consists of a series of developmental play tasks. contains two scoring systems of composite scores and percentile ranks. The normal range for composite scores is between 40-160 with mean at 100 and 0-99 for the percentile ranks. Higher scores mean a better outcome.	2 Years
Primary	Changes in neurodevelopment parameters over time utilizing an age appropriate assessment.	The determination of whether a patient received Kaufman Assessment Battery for Children-II (KABC-II) is based on an algorithm that includes the patient's calendar age and VABS-II age-equivalent score (See Outcome 1). The KABC-II is an individually administered measure of processing and reasoning abilities. The scoring range is 69 and below through 131 or greater. Higher scores mean a better outcome.	2 Years
Primary	Changes in seizure frequency over time	Seizure diary	2 Years
Secondary	Changes in communication ability over time	Observer-Reported Communication Ability (ORCA) Outcome Measure. The ORCA measure produces a single score that is an estimate of an individual's overall level of communication ability. Higher ORCA scores reflect greater communication ability; the mastery of expressive, receptive, and pragmatic types of communication and higher vocabularies for verbal words and symbols on assistive devices. The ORCA T-score range is from 26.82 to 83.24.	2 Years
Secondary	Changes in sleep behavior over time	Patient sleep habits will be assessed using Children's Sleep Habits Questionnaires (CSHQ).	2 Years
Secondary	Changes in electroencephalogram (EEG) recording over time	Standard EEG, lasting approximately 1 hour, to assess the presence of epileptiform activity.	2 Years
Secondary	Changes in motor function over time utilizing an age appropriate assessment.	The Hammersmith Infant Neurological Examination (HINE) is aimed to be used for infants between 3 and 24 months of age and assess different aspects of neurological function: cranial nerve function, movements, reflexes and protective reactions and behavior, as well as some age-dependent items that reflect the development of gross and fine motor function. Each item is scored 0-3, higher scores mean a better outcome.	2 Years
Secondary	Changes in motor function over time utilizing an age appropriate assessment.	The Gross Motor Function Measure-88 is aimed to be used for children 5 months or older of age and assess changes in gross motor function over time. Each item is scored 0-3, higher scores mean a better outcome.	2 Years